CoreCap Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

CoreCap Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$171	Hold	25	–	–	﹤0.01%	2980
2026 Q2	$235	Hold	25	–	–	﹤0.01%	2988
2026 Q1	$235	Hold	25	–	–	﹤0.01%	2745
2025 Q4	$204	Buy	+25	New	+$309	﹤0.01%	2813
2024 Q3	–	Sell	-25	Closed	-$1.13K	–	2661
2024 Q2	$1.13K	Hold	25	–	–	﹤0.01%	1382
2024 Q1	$981	Buy	+25	New	+$616	﹤0.01%	2227
2022 Q4	$83	Buy	+25	New	+$96	﹤0.01%	2319
2022 Q3	–	Sell	-25	Closed	–	–	839
2022 Q2	$0	Buy	+25	New	+$242	﹤0.01%	2155
2022 Q1	–	Sell	-25	Closed	-$1K	–	853
2021 Q4	$1K	Buy	+25	New	+$677	﹤0.01%	2085

Other funds holding CRBP

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

CoreCap Advisors's CRBP Position: Q3 2026 in Review

CoreCap Advisors held its Corbus Pharmaceuticals (CRBP) position steady in Q3 2026 at 25 shares worth $171. The position accounts for ﹤0.01% of the portfolio, ranked #2980.

CoreCap Advisors first reported a position in CRBP in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.13K in Q2 2024. 14 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

CoreCap Advisors held 25 shares of Corbus Pharmaceuticals worth $171 as of Q3 2026.
CoreCap Advisors left its Corbus Pharmaceuticals share count unchanged in Q3 2026.
Corbus Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2980 holding.
CoreCap Advisors first reported a position in Corbus Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
CoreCap Advisors's Corbus Pharmaceuticals position peaked at $1.13K in Q2 2024.
14 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.